Imiquimod 5% Cream is a Safe and Effective Self-Applied Treatment for Anogenital Warts — Results of an Open-Label, Multicentre Phase IIIB Trial
暂无分享,去创建一个
S. Garland | S. Aractingi | J. Sellors | R. Maw | A. Wikstrom | C. S. Petersen | C. Aranda
[1] H. Gollnick,et al. New patient-applied therapy for anogenital warts is rated favourably by patients , 2001, International journal of STD & AIDS.
[2] R. Angioli,et al. Self-administered topical 5% imiquimod cream for external anogenital warts in adolescent girls , 2001 .
[3] J. Kaczorowski,et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[4] C. Lacey,et al. European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts , 2000, Sexually transmitted infections.
[5] J. Kaczorowski,et al. Prevalence and predictors of human papillomavirus infection in women in Ontario, Canada. Survey of HPV in Ontario Women (SHOW) Group. , 2000, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[6] P. Langley,et al. Modeling the impact of treatment options in genital warts: patient-applied versus physician-administered therapies. , 1999, Clinical therapeutics.
[7] M. Catchpole,et al. New cases seen at genitourinary medicine clinics: England 1998. , 1999, Communicable disease report. CDR supplement.
[8] W. Cates,et al. Estimates of the Incidence and Prevalence of Sexually Transmitted Diseases in the United States , 1999 .
[9] A. Swan,et al. New cases seen at genitourinary medicine clinics: England 1997. , 1998, Communicable disease report. CDR supplement.
[10] M. Stanley,et al. A randomized, controlled, molecular study of condylomata acuminata clearance during treatment with imiquimod. , 1998, The Journal of infectious diseases.
[11] K. Workowski,et al. 1998 guidelines for treatment of sexually transmitted diseases , 1998 .
[12] C. Fairley,et al. Epidemiology of genital warts in England and Wales: 1971 to 1994. , 1997, Genitourinary medicine.
[13] I. Krantz,et al. Symptomatic genital papillomavirus infection in a community , 1996, Acta obstetricia et gynecologica Scandinavica.
[14] M. Stanley,et al. Immunological events in regressing genital warts. , 1994, American Journal of Clinical Pathology.
[15] P. Lyttle. Surveillance report: disease trends at New Zealand sexually transmitted disease clinics 1977-1993. , 1994, Genitourinary medicine.
[16] M J Reiter,et al. Inhibition of murine tumor growth by an interferon-inducing imidazoquinolinamine. , 1992, Cancer research.
[17] D. Bernstein,et al. Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection. , 1988, Antiviral research.
[18] K. Holmes,et al. Epidemiology of genital human papillomavirus infection. , 1988, Epidemiologic reviews.
[19] L. Kurland,et al. Condyloma acuminatum in Rochester, Minn., 1950-1978. I. Epidemiology and clinical features. , 1984, Archives of dermatology.
[20] L. Kurland,et al. Condyloma acuminatum in Rochester, Minn, 1950-1978. II. Anaplasias and unfavorable outcomes. , 1984, Archives of dermatology.